Geron

Yahoo Finance • 24 days ago

Geron strategic restructuring plan focuses on Rytelo growth

[Scissors separating employees on colorful blocks representing staff reduction] * Geron said that as part of its strategic restructuring plan, it will focus [https://seekingalpha.com/pr/20336521-geron-corporation-announces-strategic-res... Full story

Yahoo Finance • last month

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independ... Full story

Yahoo Finance • 3 months ago

GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron (GERN) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder of Geron securities between Februar... Full story

Yahoo Finance • 3 months ago

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders... Full story

Yahoo Finance • 3 months ago

Geron Corporation Announces Executive Leadership Transitions and Appointments

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transi... Full story

Yahoo Finance • 4 months ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 966,000 shares of its commo... Full story

Yahoo Finance • 5 months ago

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its Board of Directors as an Independent Director... Full story

Yahoo Finance • 5 months ago

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) investors... Full story

Yahoo Finance • 5 months ago

Geron Corporation’s SWOT analysis: biotech stock faces growth hurdles amid positive outlook

Geron Corporation (NASDAQ:GERN), a biotechnology company focused on developing innovative therapies for hematologic malignancies, has been navigating a complex landscape of opportunities and challenges. The company’s flagship product, Ryte... Full story

Yahoo Finance • 5 months ago

GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders... Full story

Yahoo Finance • 5 months ago

Geron outlines 20% sales force expansion and expects RYTELO impact by year-end while advancing EU launch plans

Earnings Call Insights: Geron Corporation (GERN) Q2 2025 MANAGEMENT VIEW * Dawn Carter Bir, Interim President and CEO, highlighted the appointment of Harout Semerjian as Geron's new President and CEO, noting his commercial expertise in... Full story

Yahoo Finance • 5 months ago

Geron (GERN) Q2 Revenue Jumps 5,477%

Key Points GAAP revenue reached $49.0 million in Q2 2025, beating analyst estimates for both GAAP EPS and revenue. GAAP earnings per share improved to $(0.02). RYTELO demand rose 17% quarter-over-quarter following a challenging start to t... Full story

Yahoo Finance • 5 months ago

Geron Q2 2025 Earnings Preview

* Geron (NASDAQ:GERN [https://seekingalpha.com/symbol/GERN]) is scheduled to announce Q2 earnings results on Wednesday, August 6th, before market open. * The consensus EPS Estimate is -$0.03 [https://seekingalpha.com/symbol/GERN/earnin... Full story

Yahoo Finance • 6 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Geron Corporation, Viatris, Everus Construction, and SoundHound

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain officers and directors of Geron Corporation (NASDAQ: GERN), Viatris Inc. (NASDAQ: VT... Full story

Yahoo Finance • 8 months ago

GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders f... Full story

Yahoo Finance • 8 months ago

Why Geron Corporation (GERN) Is The Best Low Priced Biotech Stock to Buy Now

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Geron Corporation (NASDAQ:GERN) stands against other best low priced biotech stocks to buy now. Is Now the... Full story

Yahoo Finance • 8 months ago

Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Gero... Full story

Yahoo Finance • 8 months ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Geron, Digimarc, XPLR, and Fluence and Encourages Investors to Contact the Firm

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Geron Corporation (NASDAQ:... Full story

Yahoo Finance • 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN). Shareholders who purchased shares of GERN during the class period listed are encouraged to co... Full story

Yahoo Finance • 8 months ago

Holzer & Holzer, LLC Reminds Investors of the May 12, 2025 Lead Plaintiff Deadline in Shareholder Class Action Lawsuits Against Geron Corporation (GERN), and Fluence Energy, Inc. (FLNC)

ATLANTA, May 06, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the May 12, 2025 deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Geron Corporation (GERN) The shareholder class... Full story